Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Apellis Pharmaceuticals Inc APLS

Healthcare Biotechnology
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related... see more

Recent & Breaking News (NDAQ:APLS)

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 7, 2021

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases

GlobeNewswire June 30, 2021

Apellis Pharmaceuticals to Host R&D Day on June 30, 2021

GlobeNewswire June 23, 2021

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Apellis Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

ACCESSWIRE IA June 9, 2021

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire June 3, 2021

Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI(TM) (pegcetacoplan) in Treatment-naïve Patients with PNH

GlobeNewswire May 25, 2021

Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI(TM) (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

GlobeNewswire May 14, 2021

Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress

GlobeNewswire May 12, 2021

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 7, 2021

Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results

GlobeNewswire April 28, 2021

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Apellis Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

PR Newswire April 26, 2021

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Apellis Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty Claims

ACCESSWIRE IA April 23, 2021

Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021

GlobeNewswire April 21, 2021

Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

GlobeNewswire April 16, 2021

Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy

GlobeNewswire April 13, 2021

Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

GlobeNewswire March 17, 2021

Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy

GlobeNewswire March 10, 2021

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 5, 2021

Apellis Provides Update on APL-9 for Severe COVID-19

GlobeNewswire March 4, 2021

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire February 25, 2021